Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for prevention of radiotherapy-induced acute toxicities in prostate cancer
IRCT2016020626401N1Phase 2Completed
- Sponsor
- Private Health Management
- Start
- Feb 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing Celecoxib with Placebo (2 arms). Primary endpoint: Radiotherapy-induced acute toxicities. Started Feb 2015; status: completed.
02
Drugs
celecoxib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on IRCT2016020626401N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016020626401N1.